Literature DB >> 26669923

SMAD3 Is Upregulated in Human Osteoarthritic Cartilage Independent of the Promoter DNA Methylation.

Erfan Aref-Eshghi1, Ming Liu1, Seyd Babak Razavi-Lopez1, Kensuke Hirasawa1, Patricia E Harper1, Glynn Martin1, Andrew Furey1, Roger Green1, Guang Sun1, Proton Rahman1, Guangju Zhai2.   

Abstract

OBJECTIVE: To compare SMAD3 gene expression between human osteoarthritic and healthy cartilage and to examine whether expression is regulated by the promoter DNA methylation of the gene.
METHODS: Human cartilage samples were collected from patients undergoing total hip/knee joint replacement surgery due to primary osteoarthritis (OA), and from patients with hip fractures as controls. DNA/RNA was extracted from the cartilage tissues. Real-time quantitative PCR was performed to measure gene expression, and Sequenom EpiTyper was used to assay DNA methylation. Mann-Whitney test was used to compare the methylation and expression levels between OA cases and controls. Spearman rank correlation coefficient was calculated to examine the association between the methylation and gene expression.
RESULTS: A total of 58 patients with OA (36 women, 22 men; mean age 64 ± 9 yrs) and 55 controls (43 women, 12 men; mean age 79 ± 10 yrs) were studied. SMAD3 expression was on average 83% higher in OA cartilage than in controls (p = 0.0005). No difference was observed for DNA methylation levels in the SMAD3 promoter region between OA cases and controls. No correlation was found between SMAD3 expression and promoter DNA methylation.
CONCLUSION: Our study demonstrates that SMAD3 is significantly overexpressed in OA. This overexpression cannot be explained by DNA methylation in the promoter region. The results suggest that the transforming growth factor-β/SMAD3 pathway may be overactivated in OA cartilage and has potential in developing targeted therapies for OA.

Entities:  

Keywords:  CARTILAGE; DNA METHYLATION; GENE EXPRESSION; OSTEOARTHRITIS; SMAD3

Mesh:

Substances:

Year:  2015        PMID: 26669923     DOI: 10.3899/jrheum.150609

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  The polymorphism of SMAD3 rs1065080 is associated with increased risk for knee osteoarthritis.

Authors:  Chao Lu; Jin Shu; Yan Han; Xiao Yu Ren; Ke Xu; Hua Fan; Ying Pu Chen; Kan Peng
Journal:  Mol Biol Rep       Date:  2019-06-10       Impact factor: 2.316

2.  Evaluation of shared genetic aetiology between osteoarthritis and bone mineral density identifies SMAD3 as a novel osteoarthritis risk locus.

Authors:  Sophie Hackinger; Katerina Trajanoska; Unnur Styrkarsdottir; Eleni Zengini; Julia Steinberg; Graham R S Ritchie; Konstantinos Hatzikotoulas; Arthur Gilly; Evangelos Evangelou; John P Kemp; David Evans; Thorvaldur Ingvarsson; Helgi Jonsson; Unnur Thorsteinsdottir; Kari Stefansson; Andrew W McCaskie; Roger A Brooks; Jeremy M Wilkinson; Fernando Rivadeneira; Eleftheria Zeggini
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

3.  Aberrant activation of latent transforming growth factor-β initiates the onset of temporomandibular joint osteoarthritis.

Authors:  Liwei Zheng; Caixia Pi; Jun Zhang; Yi Fan; Chen Cui; Yang Zhou; Jianxun Sun; Quan Yuan; Xin Xu; Ling Ye; Xu Cao; Xuedong Zhou
Journal:  Bone Res       Date:  2018-09-11       Impact factor: 13.567

4.  Genetic Variants and Protein Alterations of Selenium- and T-2 Toxin-Responsive Genes Are Associated With Chondrocytic Damage in Endemic Osteoarthropathy.

Authors:  Yujie Ning; Minhan Hu; Jiayu Diao; Yi Gong; Ruitian Huang; Sijie Chen; Feiyu Zhang; Yanli Liu; Feihong Chen; Pan Zhang; Guanghui Zhao; Yanhai Chang; Ke Xu; Rong Zhou; Cheng Li; Feng Zhang; Mikko Lammi; Xi Wang; Xiong Guo
Journal:  Front Genet       Date:  2022-01-11       Impact factor: 4.599

5.  Macrophage migration inhibitory factor may play a protective role in osteoarthritis.

Authors:  Ming Liu; Zikun Xie; Guang Sun; Liujun Chen; Dake Qi; Hongwei Zhang; Jieying Xiong; Andrew Furey; Proton Rahman; Guanghua Lei; Guangju Zhai
Journal:  Arthritis Res Ther       Date:  2021-02-20       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.